日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

MET激酶结构域中的激活点突变代表了肺癌和其他恶性肿瘤的一个独特的分子亚群,这些亚群可作为MET抑制剂的靶点。

Federica Pecci #,Seshiru Nakazawa #,Biagio Ricciuti,Guilherme Harada,Jessica K Lee,Joao V Alessi,Adriana Barrichello,Victor R Vaz,Giuseppe Lamberti,Alessandro Di Federico,Malini M Gandhi,Dimitris Gazgalis,William W Feng,Jie Jiang,Simon Baldacci,Marie-Anaïs Locquet,Felix H Gottlieb,Monica F Chen,Elinton Lee,Danielle Haradon,Anna Smokovich,Emma Voligny,Tom Nguyen,Vikas K Goel,Zachary Zimmerman,Sumandeep Atwal,Xinan Wang,Magda Bahcall,Rebecca S Heist,Sumaiya Iqbal,Nishant Gandhi,Andrew Elliott,Ari M Vanderwalde,Patrick C Ma,Balazs Halmos,Stephen V Liu,Jianwei Che,Alexa B Schrock,Alexander Drilon,Pasi A Jänne #,Mark M Awad #

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

联合使用 I 型和 II 型 MET 酪氨酸激酶抑制剂作为预防耐药性的治疗方法

Magda Bahcall, Cloud P Paweletz, Yanan Kuang, Luke J Taus, Taebo Sim, Nam Doo Kim, Kshiti H Dholakia, Christie J Lau, Prafulla C Gokhale, Pratik R Chopade, Fangxin Hong, Zihan Wei, Jens Köhler, Paul T Kirschmeier, Jiannan Guo, Sujuan Guo, Stephen Wang, Pasi A Jänne

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

通过 YAP 介导的凋亡途径转录重编程,治疗诱导肿瘤休眠

Kari J Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Amir Vajdi, Erik H Knelson, Yingtian Xie, Klothilda Lim, Paloma Cejas, Andrew Portell, Patrick H Lizotte, Scott B Ficarro, Shuai Li, Ting Chen, Heidi M Haikala, Haiyun Wang, Magda Bahcall, Yang Gao, Sophia Shalhout, Steffen Boettcher, Bo

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer

使用体外患者来源的肿瘤器官型球体来识别 HER2 突变型非小细胞肺癌的联合疗法

Elena Ivanova, Mari Kuraguchi, Man Xu, Andrew J Portell, Luke Taus, Irmina Diala, Alshad S Lalani, Jihyun Choi, Emily S Chambers, Shuai Li, Shengwu Liu, Ting Chen, Thanh U Barbie, Geoffrey R Oxnard, Jacob J Haworth, Kwok-Kin Wong, Suzanne E Dahlberg, Amir A Aref, David A Barbie, Magda Bahcall, Cloud

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC

MET 外显子 14 突变型 NSCLC 患者对 MET 酪氨酸激酶抑制剂获得性耐药的分子机制

Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen, Marina S D Milan, Deepti Venkatraman, Renato Umeton, Cloud P Paweletz, Adem Albayrak, Andrew D Cherniack, Kristin S Price, Stephen R Fairclough, Mi

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer

野生型 KRAS 的扩增导致 MET 外显子 14 突变型非小细胞肺癌对克唑替尼产生耐药性

Magda Bahcall, Mark M Awad, Lynette M Sholl, Frederick H Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V Ivanova, Giulia C Leonardi, Bryan C Ulrich, Cloud P Paweletz, Paul T Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J Nagy, Richard B Lanman, Marzia

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

化学诱导间变性淋巴瘤激酶 (ALK) 降解

Chelsea E Powell, Yang Gao, Li Tan, Katherine A Donovan, Radosław P Nowak, Amanda Loehr, Magda Bahcall, Eric S Fischer, Pasi A Jänne, Rani E George, Nathanael S Gray

Discovery of a potent dual ALK and EGFR T790M inhibitor

发现有效的双重 ALK 和 EGFR T790M 抑制剂

Jaebong Jang, Jung Beom Son, Ciric To, Magda Bahcall, So Young Kim, Seock Yong Kang, Mierzhati Mushajiang, Younho Lee, Pasi A Jänne, Hwan Geun Choi, Nathanael S Gray